Cargando…
Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study
BACKGROUND: Intraocular lymphoma (IOL) is a rare malignant lymphoma that most closely resembles a diffuse large B-cell lymphoma, and it is a subtype of primary central nervous system lymphoma (PCNSL). IOL is located inside the eye in the retina, uvea, and/or optic nerve. We retrospectively analyzed...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705050/ https://www.ncbi.nlm.nih.gov/pubmed/26770952 http://dx.doi.org/10.5045/br.2015.50.4.242 |
_version_ | 1782408957904551936 |
---|---|
author | Lee, Seul Kim, Moon Jin Kim, Jin Seok Oh, Sung Yong Kim, Seok Jin Kwon, Yoon Hyung Chung, In Young Kang, Jung Hun Yang, Deok-Hwan Kang, Hye Jin Yoon, Dok Hyun Kim, Won Seog Kim, Hyo-Jin Suh, Cheolwon |
author_facet | Lee, Seul Kim, Moon Jin Kim, Jin Seok Oh, Sung Yong Kim, Seok Jin Kwon, Yoon Hyung Chung, In Young Kang, Jung Hun Yang, Deok-Hwan Kang, Hye Jin Yoon, Dok Hyun Kim, Won Seog Kim, Hyo-Jin Suh, Cheolwon |
author_sort | Lee, Seul |
collection | PubMed |
description | BACKGROUND: Intraocular lymphoma (IOL) is a rare malignant lymphoma that most closely resembles a diffuse large B-cell lymphoma, and it is a subtype of primary central nervous system lymphoma (PCNSL). IOL is located inside the eye in the retina, uvea, and/or optic nerve. We retrospectively analyzed IOL patient data to identify treatment patterns and survival rates in Korea. METHODS: Cytological confirmation for a diagnosis of IOL was performed for all patients. The clinical data collected from medical records included Ann Arbor stage, International Prognostic Index, performance status, date of diagnosis, treatment modality and response, date of relapse, and date of last follow-up. RESULTS: Twenty patients who were diagnosed with IOL, between December 2007 and June 2014 at multiple centers in Korea, were included in the analysis. Four patients were diagnosed with IOL alone, not involving the CNS. Two patients with isolated IOL later developed PCNSL. Nine patients developed CNS lesions before the onset of ocular lymphoma. Five patients had simultaneous onset in the eye and CNS. Twelve patients were treated by intravitreal injection of methotrexate for IOL. The median progression-free survival (PFS) for patients was 19.7 months (95% CI, 8.7-30.7 mo). The estimated 3-year overall survival (OS) for all patients was 75.1%. CONCLUSION: Treatment for IOL patients included radiotherapy and intraocular chemotherapy. IOL patients showed favorable PFS and OS. These patients would require long-term follow-up to identify relapse and adverse effects of radiotherapy or intraocular chemotherapy. |
format | Online Article Text |
id | pubmed-4705050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis |
record_format | MEDLINE/PubMed |
spelling | pubmed-47050502016-01-14 Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study Lee, Seul Kim, Moon Jin Kim, Jin Seok Oh, Sung Yong Kim, Seok Jin Kwon, Yoon Hyung Chung, In Young Kang, Jung Hun Yang, Deok-Hwan Kang, Hye Jin Yoon, Dok Hyun Kim, Won Seog Kim, Hyo-Jin Suh, Cheolwon Blood Res Original Article BACKGROUND: Intraocular lymphoma (IOL) is a rare malignant lymphoma that most closely resembles a diffuse large B-cell lymphoma, and it is a subtype of primary central nervous system lymphoma (PCNSL). IOL is located inside the eye in the retina, uvea, and/or optic nerve. We retrospectively analyzed IOL patient data to identify treatment patterns and survival rates in Korea. METHODS: Cytological confirmation for a diagnosis of IOL was performed for all patients. The clinical data collected from medical records included Ann Arbor stage, International Prognostic Index, performance status, date of diagnosis, treatment modality and response, date of relapse, and date of last follow-up. RESULTS: Twenty patients who were diagnosed with IOL, between December 2007 and June 2014 at multiple centers in Korea, were included in the analysis. Four patients were diagnosed with IOL alone, not involving the CNS. Two patients with isolated IOL later developed PCNSL. Nine patients developed CNS lesions before the onset of ocular lymphoma. Five patients had simultaneous onset in the eye and CNS. Twelve patients were treated by intravitreal injection of methotrexate for IOL. The median progression-free survival (PFS) for patients was 19.7 months (95% CI, 8.7-30.7 mo). The estimated 3-year overall survival (OS) for all patients was 75.1%. CONCLUSION: Treatment for IOL patients included radiotherapy and intraocular chemotherapy. IOL patients showed favorable PFS and OS. These patients would require long-term follow-up to identify relapse and adverse effects of radiotherapy or intraocular chemotherapy. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2015-12 2015-12-21 /pmc/articles/PMC4705050/ /pubmed/26770952 http://dx.doi.org/10.5045/br.2015.50.4.242 Text en © 2015 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lee, Seul Kim, Moon Jin Kim, Jin Seok Oh, Sung Yong Kim, Seok Jin Kwon, Yoon Hyung Chung, In Young Kang, Jung Hun Yang, Deok-Hwan Kang, Hye Jin Yoon, Dok Hyun Kim, Won Seog Kim, Hyo-Jin Suh, Cheolwon Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study |
title | Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study |
title_full | Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study |
title_fullStr | Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study |
title_full_unstemmed | Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study |
title_short | Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study |
title_sort | intraocular lymphoma in korea: the consortium for improving survival of lymphoma (cisl) study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705050/ https://www.ncbi.nlm.nih.gov/pubmed/26770952 http://dx.doi.org/10.5045/br.2015.50.4.242 |
work_keys_str_mv | AT leeseul intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT kimmoonjin intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT kimjinseok intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT ohsungyong intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT kimseokjin intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT kwonyoonhyung intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT chunginyoung intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT kangjunghun intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT yangdeokhwan intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT kanghyejin intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT yoondokhyun intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT kimwonseog intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT kimhyojin intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy AT suhcheolwon intraocularlymphomainkoreatheconsortiumforimprovingsurvivaloflymphomacislstudy |